Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/23014
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMitlianga, P. G.en
dc.contributor.authorKyritsis, A. P.en
dc.contributor.authorGomez-Manzano, C.en
dc.contributor.authorLemoine, M. G.en
dc.contributor.authorHu, M.en
dc.contributor.authorLiu, T. J.en
dc.contributor.authorYung, W. K.en
dc.contributor.authorFueyo, J.en
dc.date.accessioned2015-11-24T19:30:03Z-
dc.date.available2015-11-24T19:30:03Z-
dc.identifier.issn1019-6439-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23014-
dc.rightsDefault Licence-
dc.subjectActins/metabolismen
dc.subjectAdenoviridaeen
dc.subjectApoptosis/*physiologyen
dc.subjectE2F2 Transcription Factoren
dc.subjectGenes, p53/*physiologyen
dc.subjectGlioblastoma/*metabolism/therapyen
dc.subjectGlioma/*metabolism/therapyen
dc.subjectHumansen
dc.subject*Nuclear Proteinsen
dc.subjectProto-Oncogene Proteins/*metabolismen
dc.subjectProto-Oncogene Proteins c-mdm2en
dc.subjectTranscription Factors/genetics/*metabolismen
dc.subjectTumor Cells, Cultured/metabolismen
dc.titleCo-expression of E2F-2 enhances the p53 anti-cancer effect in human glioma cellsen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/11172602-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2001-
heal.abstractGliomas are highly resistant to conventional treatment. Improved knowledge of the molecular defects of glioma cells offers new avenues for the development of gene therapy strategies. Transfer of the p53 gene has proven effective in suppressing proliferation in human glioma cell lines. However, several human glioma cell lines are resistant to p53-induced cell death. The E2F family of transcription factors are pivotal for the regulation of cell-cycle and cell-death related genes in gliomas. In the present study, we sought a more effective strategy for glioma treatment by examining the therapeutic potential of the simultaneous transfer of p53 and E2F-2 to gliomas. Trypan blue cell viability assays and flow cytometric cell-cycle analysis demonstrated that the transfer of both p53 and E2F-2 induced cell death in D-54 MG, a p53-resistant glioma cell line. In addition, transfer of E2F-2 did not interfere with the apoptotic properties of exogenous wild-type p53 in U-251 MG cells. Finally, the expression of E2F-2 in D-54 MG cells suppressed the expression of the apoptotic molecule mdm-2 induced by exogenous p53 in these cells. These results show that co-expression of E2F-2 and p53 enhances the anti-cancer effect of p53 in gliomas.en
heal.journalNameInt J Oncolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons